Whitehawk Therapeutics, Inc.
WHWKNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M | $14.0M |
| Operating income | −$114.4M | −$67.5M | −$71.9M | −$62.7M | −$111.2M | −$2.5M |
| Net income | −$20.6M | −$63.7M | −$65.8M | −$60.5M | −$110.1M | −$3.5M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M | $18.8M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M | $31.3M |
| Equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M | −$12.4M |
| EPS (diluted) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | — |
| Shares out. | 46.8M | 24.6M | 24.4M | 20.9M | 47.3M | 40.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1601.1%
- Net margin
- −288.3%
- Return on equity
- −15.1%
- Return on assets
- −13.7%
- Return on capital (ROCE)
- −83.9%
- Liabilities / assets
- 9.6%
- Debt / equity
- 0.11×
- Book value / share
- $2.91
- Revenue growth (YoY)
- −72.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.98safe
- Accruals / assets
- 50.9%high accruals
- Beneish M-Score
- -2.16normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2028-02A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Phase 1Recruitingreadout ~2028-10Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Acuta Capital Partners, LlcActivist (13D)May 18, 2026
- Avoro Capital Advisors LlcActivist (13D)May 14, 2026
- Coastlands Capital LpPassive (13G)Aug 25, 2025
- Orbimed Advisors LlcPassive (13G)May 15, 2025
- Point72 Asset Management, L.P.Passive (13G)May 15, 2025
- Suvretta Capital Management, LlcPassive (13G)Mar 11, 2025
- Abg Management Ltd.Passive (13G)Mar 10, 2025
- Desai NeilActivist (13D)Mar 6, 2025
- Bml Investment Partners, L.P.Activist (13D)Mar 5, 2025
- Qvt Financial LpPassive (13G)Feb 14, 2025
- Ecor1 Capital, LlcPassive (13G)Feb 14, 2025
- Satter Muneer APassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 854,980 | 1.4 | +3.7% |
| Apr 30, 2026 | 824,655 | 3.8 | +5.7% |
| Apr 15, 2026 | 780,056 | 3.7 | +12.4% |
| Mar 31, 2026 | 693,909 | 3.9 | -3.9% |
| Mar 13, 2026 | 722,187 | 3.0 | -7.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 21, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureMay 13, 2026
- Results of operationsMay 7, 2026
- Results of operationsMar 12, 2026
- Results of operationsNov 6, 2025
- Results of operationsAug 7, 2025
- Shareholder voteJun 13, 2025
- Results of operationsMay 8, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.